PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma

Overview of attention for article published in BMC Cancer, March 2021

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (78th percentile)
High Attention Score compared to outputs of the same age and source (91st percentile)

So far, Altmetric has seen 15 X posts from 15 X users, with an upper bound of 77,053 followers.

New in #BMCCancer: trial protocol for PRIME-HCC Phase 1b study 👇

RT @IHepatology: Great new study on neoadjuvant #immunotherapy in early-stage #HCC from @DJPinato and colleagues @IHepatology @ImperialMD…

RT @IHepatology: Great new study on neoadjuvant #immunotherapy in early-stage #HCC from @DJPinato and colleagues @IHepatology @ImperialMD…

Great new study on neoadjuvant #immunotherapy in early-stage #HCC from @DJPinato and colleagues @IHepatology @ImperialMDR @ImperialSandC

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 11 additional X posts.